Nasdaq Gains 100 Points; ISM manufacturing PMI Slips In September
U.S. stocks edged higher Thursday; Nasdaq rose 0.37%, energy led gains, Accenture surged 18%, and Corteva plunged 84%.
Stocks · News reference
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
Foghorn Therapeutics stock drops as Eli Lilly ends partnership, prompting a 40% workforce cut to extend cash runway into 2029 while pivoting pipeline.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dow Falls Over 200 Points; Micron Earnings Top Views
U.S. stocks slipped Thursday as the Dow fell over 200 points; energy and oil rose, Micron beat estimates, and European markets declined.
Foghorn Therapeutics shares are trading lower after the company and Lilly decided not to advance FHD-909 into the expansion phase and discontinued their SMARCA2 degrader collaboration.
Eli Lilly's Once-Daily Weight Loss Pill Orforglipron Shows Significant Reduction in Heart Disease Risk
Eli Lilly says Phase 3 Foundayo (Orforglipron) data show reduced cardiovascular and type 2 diabetes risks in adults with obesity.
Foghorn Therapeutic Announces That The Company And Lilly Will Not Advance The FHD-909 Program Into The Clinical Development Expansion Phase
Novo Announces Wegovy Liver Fat Reductions To Normal Levels In 9 Out Of 10 Adults With Obesity And Excess Liver Fat